Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

Pfizer

Status: Withdrawn

Conditions: Neovascular Age-related Macular Degeneration

Treatments: Drug: Macugen

Study type: Observational

Funder types: Industry

Identifiers

NCT00820742

A5751025

Details and patient eligibility

About

An open label, non-comparative, multicenter, non-interventional, post marketing surveillance study to evaluate the overall safety and tolerability of pegaptanib sodium(Macugen) in the treatment of Filipino patients with neovascular age-related macular degeneration based on incidence of adverse events and to evaluate the efficacy based on visual acuity, and the patient's and physician's overall satisfaction with tolerability and efficacy.

Full description

Open-label, non-comparative, non-interventional study

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have at least one eye which was diagnosed with neovascular degeneration

Exclusion criteria

• Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, multifocal choroiditis

Trial design

0 participants in 1 patient group

Phase IV Post Marketing Surveillance Study

Description:

Open-label, observational study

Treatment:

Drug: Macugen